Regeneron and Sanofi have expanded their antibody collaboration to include new candidates targeting IL-4 and IL-13 pathways for next-generation inflammation and immunology treatments. The deal provides Regeneron with $1 billion upfront and up to $7 billion in milestone payments, with profits split evenly for new products. This partnership aims to address challenges from Dupixent's patent expiry and emerging competitors, with potential new therapies launching from 2030 onward. The milestone payments are expected to balance Regeneron's increased R&D costs, leveraging existing commercial infrastructure to maximize future market impact.
As of Oct 02, 2026 00:41 WIB, Regeneron (REGN) trades at USD 740.98, down 2.28% for the day and closer to its 52-week high of USD 852.03 than its low of USD 557.73. In contrast, Sanofi (SNY) is priced at USD 40.90, just above its 52-week low of USD 40.74 and well below its 52-week high of USD 52.34, with a smaller 1-day decline of 0.80%. Both stocks show strong buy interest on Pluang, despite their differing dividend yields and market caps.
Jefferies increased its price target for Regeneron to $930, citing an expanded partnership with Sanofi to develop four new long-acting antibodies targeting inflammatory pathways. Sanofi will pay Regeneron $1 billion upfront, with potential milestone ...
Citigroup has maintained a Neutral rating on Regeneron Pharmaceuticals due to increasing competition in the ophthalmology sector. Kodiak Sciences reported positive Phase 3 trial results for its eye drugs, challenging Regeneron's key product, Eylea, e...
Biohaven announced that Phase 1 data for BHV-1530, a novel FGFR3-targeting antibody-drug conjugate for advanced cancers, will be presented at the ENA 2026 symposium. BHV-1530 has demonstrated early clinical activity with a favorable safety profile, a...
